Amryt Pharma Share Discussion Threads

[moneytree1] 11/4/2018 14:52

calm down Pappy.

Have a nice cup of tea.

[bazworth] 10/4/2018 23:48

For goodness sake!

[papillon] 10/4/2018 22:46

You can read and understand the writing on your lavatory wall, pottermagic, but you seem to be incapable of reading and understanding of what I wrote in that post! :-(

Strangeman hit the nail on the head. I WAS TALKING ABOUT THE INTRADAY HIGH OF 34p REACHED BY FAST IN 2012 PRIOR TO THE 2016 8 FOR 1 CONSOLIDATION DURING THE RTO TO FORM AMYT. IF YOU MULTIPLY 34p BY 8 YOU GET £2.72p. SURELY EVEN YOU CAN UNDERSTAND THAT, POTTERMAGIC? Sorry about the use of the Caps lock, but it's often the only way to get through to some people!! :-)

i originally bought FAST shares, over 3 years ago @ less than 3p, so I will break even on my FAST purchases below 24p after taking into account the 8 for 1 consolidation.

In fact I break even around 20p after taking into account the 8 for 1 consolidation.

EDIT: Here's the FAST chart, pottermagic, just for you. You can see in 2012 it rose to over 30p. YOU HAVE TO MULTIPLY EVERY FAST share price BY 8 to get the EQUIVALENT AMYT share price Can you understand that pottermagic? Can you grasp that? Only those FAST shareholders who bought sub 3p (from just before the end of 2014 and onwards) can achieve breakeven on those FAST shares when AMYT achieves 24p.

[strangeman] 10/4/2018 21:46

8 for 1 consolidation 2 years ago next week might have something to do with it.

[papillon] 10/4/2018 16:43

moneytree110 Apr '18 - 16:07 - 2594 of 2594 (Filtered)

Thank the Lord! I thought for a moment that my stalker had forshaken me! Thankfully he's returned. :-) It's just a shame that I can't see what he's written. Perhaps he's also got a lavatory wall, like pottermagic, that can foretell the future? :-)

PS. For AMYT to be successful it needs to buck the overwhelming trend that says almost all AIM listed biopharmas turn out to be awful investments for long term holders. One thing in it's favour is that AMYT hasn't yet been exposed to the ramping hype and high expectations that almost all AIM listed biopharmas are subjected to at some time.

[moneytree1] 10/4/2018 16:07

that's why you were cleaned out pappy.

if youd leave the market alone youd be able to put the heating on a little more.

poor old pappy.atb

[papillon] 10/4/2018 16:01

I'm still waiting, greendragon, for pottermagic to tell us what was written about AMYT on that (lavatory) wall. How negative was it? I was bemoaning my lack of a crystal ball, but it looks like I might not need one if pottermagic can foretell the future by reading what's written on his wall. If only he would inform us of what was written there. I need a reliable forecaster of the future as my charts have proved to be fallible in the past. Should I sell all my AMYT shares immmediately, pottermagic? Have you sold all of yours after reading what was written on your wall?

PS. I was looking at the FAST chart, greendragon (I'm at a loose end as I've a heavy cold). Back in late 2012 it reached an intraday high of 34p. For buyers of FAST back then, who still hold those shares, via AMYT, they will need to see an AMYT share price of 8 x 34p = 272p to break even!! Of course there might NOT be anyone mug enough, from back in late 2012, still holding those FAST shares via AMYT!!

FAST is proof, if proof be needed, that investing in an AIM listed O&G explorer when it's riding high, following on from message board ramping hype and unrealistic expectation, can seriously damge your wealth. Unfortunately I could substitute AIM listed biopharma instead of AIM listed O&G explorer in my previous sentence and the result would be the same!

[greendragon777] 09/4/2018 23:08

LMAO....you crack me up on here sometimes Paps! 😂

[papillon] 09/4/2018 23:01

Was it the writing on the lavatory wall, pottermagic? :-)

If it's not too obscene could you please repeat what that writing said? LOL.

PS. I go by the AMYT chart, whereas you, evidently, go by the writing on the (lavatory) wall. I wonder which is the least accurate predictor of the future? :-)

[papillon] 09/4/2018 19:36

LOL, bazworth. My posting on here is definitely an addiction, but whether it turns out to be harmless (and doesn't lose me money!) we shall have to wait and see. You will notice that I haven't given my opinion on AMYT's future prospects and I've given no future share price forecasts. :-)

I don't know where the AMYT share price is going in the short, medium, or long term (that will depend on the news it issues in RNS's and I haven't a crystal ball), though if the share price stays above my strong chart support around 17.3p I'll continue to hold all of my 27,215 shares. Whether I'll still be holding all those 27,215 shares after the next RNS (likely to be the 2017 final results within the next 2 weeks) I have no idea.

There is strong chart resistance @ circa 20.3p. Will the AMYT share price rise above that resistance and then break above further chart resistance @ circa 27p? I have no idea as that will no doubt depend on the newsflow in the coming months of which I am, unfortunately, completely ignorant. Fingers crossed the newsflow is good.

I'll continue to post my AMYT charts.

PS. I'm rather disappointed that my stalker, moneytree, hasn't posted on here so far today. :-)

[bazworth] 09/4/2018 19:03

papillon, lets face it, you couldn’t resist posting here if you tried! Would appear to be a harmless addiction. Goodness only knows what you will be like when we sail through an share price of £1++++!!!! (tongue firmly in cheek)

Cheers!!

[papillon] 09/4/2018 12:42

Well my strong chart support, @ circa 17.3p, seems to be holding. Couple of reasonable sized buys just gone through @ very near the full, quoted, asking price of 18p. share price rise in build up to the 2017 final results due middle of this month?

[papillon] 09/4/2018 11:46

Someone "rolled over" 100k @ the 17.20p bid price @ 8:26:44 & 8:26:54 this morning. Hope he knows what he's doing! LOL.

2017 Final results RNS promised for mid April. Possibly late this week? Probably early next week?

[moneytree1] 08/4/2018 16:16

what if you sell them and the next day they shoot up Pappy?

[bageo] 08/4/2018 15:28

Diamondstar
Some really interesting points, thanks.

I think the use or sales agents currently (Lojuxta) for many countries is a smart move - this could change with more products.
With only a few potential patients for countries such as Switzerland I can imagine it would only need 1 day a week to cover this. You either land up having an employee covering multiple countries with attendant costs (and knowledge/language needs) or they are very part time.

You only need to look at Vernalis to see the costs of having your own sales force (mass market product rather than limited sites). The $200k per person for a sales force is useful information.


On excluding the Simplex patients from AP101 trials this makes sense. I would assume from what has been said that this could be addressed by changing trial design - but there is no point doing this now but could follow post approval of the more challenging cases. I would foresee a shorter trial length e.g check improvement after 7 or 14 days to get a noticeable difference between current treatment and AP1010 for simplex. Clearly this trial design would not be suitable for the more challenging EB categories with longer healing (or not) times.

[greendragon777] 08/4/2018 13:48

This forum has been pretty lively of late! :-)

Very interesting discussion between Sidam and Diamondstar. It concerns me greatly to see Diamonstar reduce his AMYT position by 50%....gulp!

@Diaomstar Whilst I respect your decision 100% in reducing your position in AMYT, I am surprised that you did so if ultimately the adjustment in the trials should increase the chances of success for AP101. When you say that you would have expected an uplift of 30-40% in the share price after Zoblisa's failure, is it possible that the market just didn't see any change to the risk of trial success/failure hence no movement in the sp? It could also be argued why the share price hasn't gone up after the recent announcement if it effectively increases the chances of success. Although it could have been offset by the extra delays and risks associated with such delays etc (ie- running out of cash and first mover advantage etc).

You gave a price projection at the various milestones a few months back based on your analysis of AMYT. Would you care to do another based on your current view of AMYT?

If anything I am slightly more bullish on AMYT given that the trial adjustment should increase it's chances of success but I also realize that I was perhaps overly optimistic previously given how precarious the trials now look in it's old form.....we have obviously dodged a bullet on that one!

[bazworth] 06/4/2018 17:54

Well done!